Lin Elizabeth Yeu

Chief Medical Officer

Lin Elizabeth Yeu has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Sep 3, 2026.

On the most recent filing, Lin Elizabeth Yeu is listed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc. Inside the rolling window, Lin Elizabeth Yeu reported no open-market purchases and 6 open-market sales totaling $1.1M in TARS. The largest disclosed transaction in the window is a sale of 6,977 TARS shares on Sep 2, 2026, worth $558K.

Companies traded

Other insiders at TARS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.1M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
TARSSale$340KSep 3SEC ↗
TARSSale$558KSep 3SEC ↗
TARSSale$26KMar 19SEC ↗
TARSSale$26KMar 19SEC ↗
TARSSale$26KMar 19SEC ↗
TARSSale$165KDec 17SEC ↗

Frequently asked questions

How many SEC Form 4 filings has Lin Elizabeth Yeu made?

Lin Elizabeth Yeu has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.

Which companies does Lin Elizabeth Yeu trade?

Lin Elizabeth Yeu has filed SEC Form 4 disclosures for 1 company, including TARS.

When was Lin Elizabeth Yeu's most recent SEC Form 4 filing?

Lin Elizabeth Yeu's most recent SEC Form 4 filing on Tracefour is dated Sep 3, 2026.

What is Lin Elizabeth Yeu's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Lin Elizabeth Yeu is listed as Chief Medical Officer.

What is Lin Elizabeth Yeu's total buy and sell value in the current window?

Inside the rolling retention window, Lin Elizabeth Yeu bought $0 and sold $1.1M based on SEC Form 4 filings.

What was Lin Elizabeth Yeu's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 6,977 TARS shares on 2026-09-02, worth $558K, per SEC Form 4 filings.